Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC)

NCT01637402 is registered in ClinicalTrials.gov with Terence Friedlander, MD as lead sponsor.

NCT NCT01637402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01637402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC)
Lead sponsor
Terence Friedlander, MD
Phase
Phase 2
Overall status
Completed
Start date
March 13, 2013
Completion date
February 27, 2017
Enrollment
41 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

castration resistant prostate cancer